Canaccord Genuity analyst Arlinda Lee reiterated a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI) today and set a price target of $27. The company’s shares opened today at $18.38, close to its 52-week high of $20.39.
According to TipRanks.com, Lee is a 1-star analyst with an average return of 0.0% and a 41.2% success rate. Lee covers the Healthcare sector, focusing on stocks such as Eloxx Pharmaceuticals Inc, Aquinox Pharmaceuticals, and Zynerba Pharmaceuticals.
Currently, the analyst consensus on Karyopharm Therapeutics is a Strong Buy with an average price target of $26, a 41.5% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $30 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $20.39 and a one-year low of $8. Currently, Karyopharm Therapeutics has an average volume of 596.5K.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company, The engages in the discovery, development, and commercialization of drugs to treat cancer and other major diseases. The company intends to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
